ACAD - Company ID 0001070494
ACADIA PHARMACEUTICALS INC trades as ACAD and has a market capitalization of $4.47 B, making it the #1507 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.07B, up 11.9% from the prior year and net income of $391.00M. This page tracks ACADIA PHARMACEUTICALS INC through 1,357 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years ACADIA PHARMACEUTICALS INC's revenue grew from $17.33M to $1.07B, a compound annual growth rate of 58.1%. Net profit margin expanded from -1565.9% to 36.5% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-06 |
| Insider trade | 4 | 2026-05-05 |
| Insider trade | 4 | 2026-05-05 |
| Major company event | 8-K | 2026-05-01 |
| SCHEDULE 13G | - | 2026-04-28 |
| Annual report to shareholders | ARS | 2026-04-24 |
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview · Total revenues of $1.22 to $1.28 billion. · NUPLAZID ...
For the fourth quarter of 2024, Acadia reported net income of $143.7 million, or $0.86 per common share, compared to a net income of $45.8 ...
First quarter total revenues of $244.3 million, up 19% year-over-year. - First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, ...
The largest companies sharing ACADIA PHARMACEUTICALS INC's SEC industry classification (pharmaceutical preparations).
ACADIA PHARMACEUTICALS INC (ACAD) has a market capitalization of $4.47 B as of 2026-07-09, ranking #1507 among US-listed companies.
ACADIA PHARMACEUTICALS INC reported revenue of $1.07B for fiscal year 2025, an increase of 11.9% year over year.
Yes. ACADIA PHARMACEUTICALS INC reported net income of $391.00M in its latest fiscal year.